The Role of Probiotics in the Treatment of Irritable Bowel Syndrome

Bioactive Foods in Promoting Health

Volumn , Issue , 2010, Pages 513-528

  Parkes, Gareth C ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884437583     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374938-3.00030-X     Document Type: Chapter

References (123)

1. Thompson W.G., Longstreth G.F., Drossman D.A., et al. Functional bowel disorders and functional abdominal pain. Gut 1999, 45(Suppl. 2):II43-II47.
2. Chaudhary N.A., Truelove S.C. The irritable colon syndrome. A study of the clinical features, predisposing causes, and prognosis in 130 cases. The Quarterly Journal of Medicine 1962, 31:307-322.
3. Manning A.P., Thompson W.G., Heaton K.W., Morris A.F. Towards positive diagnosis of the irritable bowel. British Medical Journal 1978, 2:653-654.
4. Thompson W.G., Creed F., Drossman D.A. Functional bowel disorders and functional abdominal pain. Gastroenterology International 1992, 5:75-91.
5. Longstreth G.F., Thompson W.G., Chey W.D., et al. Functional bowel disorders. Gastroenterology 2006, 130:1480-1491.
6. Bommelaer G., Poynard T., Le P.C., et al. Prevalence of irritable bowel syndrome (IBS) and variability of diagnostic criteria. Gastroentérologie Clinique et Biologique 2004, 28:554-561.
7. Kellow J.E., Azpiroz F., Delvaux M., et al. Applied principles of neurogastroenterology: Physiology/motility sensation. Gastroenterology 2006, 130:1412-1420.
8. Parkes G.C., BrostoffJ., Whelan K., Sanderson J.D. Gastrointestinal microbiota in irritable bowel syndrome: their role in its pathogenesis and treatment 2. American Journal of Gastroenterol 2008, 103:1557-1567.
9. Food and Agriculture Organization of the United Nations and World Health Organization Expert Consultation Report (2001). Evaluation of health and nutritional properties of probiotics in food, including powder milk with the live lactic acid bacteria. http://www.who.int/foodsafety/publications/fs_management/en/probiotics.p df.
10. Parkes G.C., Sanderson J.D., Whelan K. The mechanisms and efficacy of probiotics in the prevention of Clostridium difficile-associated diarrhea. Lancet Infectious Diseases 2009, 9:237-244.
11. Kruis W., Fric P., Pokrotnieks J., et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004, 53:1617-1623.
12. Van Niel C.W., Feudtner C., Garrison M.M., Christakis D.A. Lactobacillus therapy for acute infectious diarrhea in children: A meta-analysis. Pediatrics 2002, 109:678-684.
13. Szajewska H., Skorka A., Ruszczynski M., Gieruszczak-Bialek D. Meta-analysis: Lactobacillus GG for treating acute diarrhea in children. Alimentary Pharmacology & Therapeutics 2007, 25:871-881.
14. Szajewska H., Skorka A., Dylag M. Meta-analysis: Saccharomyces boulardii for treating acute diarrhea in children. Alimentary Pharmacology & Therapeutics 2007, 25:257-264.
15. Alfaleh, K., & Bassler, D. (2008). Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database of Systematic Reviews, CD005496.
16. Balsari A., Ceccarelli A., Dubini F., et al. The fecal microbial population in the irritable bowel syndrome. Microbiologica 1982, 5:185-194.
17. Si J.M., Yu Y.C., Fan Y.J., Chen S.J. Intestinal microecology and quality of life in irritable bowel syndrome patients. World Journal of Gastroenterol 2004, 10:1802-1805.
18. Suau A., Bonnet R., Sutren M., et al. Direct analysis of genes encoding 16S rRNA from complex communities reveals many novel molecular species within the human gut. Applied and Environmental Microbiology 1999, 65:4799-4807.
19. Malinen E., Rinttila T., Kajander K., et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. The American Journal of Gastroenterology 2005, 100:373-382.
20. Kassinen A., Krogius-Kurikka L., Makivuokko H., et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 2007, 133:24-33.
21. Parkes G.C., Rayment N.B., Hudspith B.N., et al. Sub-groups of irritable bowel syndrome have a distinct colonic mucosa-associated microbiota. Gut 2009, 58(Suppl):A157-A172.
22. Spiller R.C., Jenkins D., Thornley J.P., et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000, 47:804-811.
23. Chadwick V.S., Chen W., Shu D., et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002, 122:1778-1783.
24. Chadwick V.S., Chen W., Shu D., et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002, 122:1778-1783.
25. Guilarte M., Santos J., de Torres I., et al. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut 2007, 56:203-209.
26. O'Sullivan M., Clayton N., Breslin N.P., et al. Increased mast cells in the irritable bowel syndrome. Neurogastroenterology and Motility 2000, 12:449-457.
27. Weston A.P., Biddle W.L., Bhatia P.S., Miner P.B. Terminal ileal mucosal mast cells in irritable bowel syndrome. Digestive Diseases and Sciences 1993, 38:1590-1595.
28. Spiller R.C., Jenkins D., Thornley J.P., et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000, 47:804-811.
29. Spiller R.C., Jenkins D., Thornley J.P., et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000, 47:804-811.
30. Bradesi S., McRoberts J.A., Anton P.A., Mayer E.A. Inflammatory bowel disease and irritable bowel syndrome: Separate or unified?. Current Opinion in Gastroenterology 2003, 19:336-342.
31. Spiller R.C., Jenkins D., Thornley J.P., et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000, 47:804-811.
32. Marshall J.K., Thabane M., Garg A.X., et al. Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Gastroenterology 2006, 131:445-450.
33. Hungin A.P., Whorwell P.J., Tack J., Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Alimentary Pharmacology & Therapeutics 2003, 17:643-650.
34. Houghton L.A., Lea R., Agrawal A., et al. Relationship of abdominal bloating to distention in irritable bowel syndrome and effect of bowel habit. Gastroenterology 2006, 131:1003-1010.
35. Koide A., Yamaguchi T., Odaka T., et al. Quantitative analysis of bowel gas using plain abdominal radiograph in patients with irritable bowel syndrome. The American Journal of Gastroenterology 2000, 95:1735-1741.
36. Perez F., Accarino A., Azpiroz F., et al. Abdominal bloating: Distinctive features of organic versus functional disorder. Gut 2007, 56:A39.
37. Hasler W.L. Lactulose breath testing, bacterial overgrowth, and IBS: Just a lot of hot air?. Gastroenterology 2003, 125:1898-1900.
38. Mishkin D., Mishkin S. Re: Pimentel et al., Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. The American Journal of Gastroenterology 2001, 96:2505-2506.
39. Riordan S.M., McIver C.J., Duncombe V.M., et al. Small intestinal bacterial overgrowth and the irritable bowel syndrome. The American Journal of Gastroenterology 2001, 96:2506-2508.
40. Walters B., Vanner S.J. Detection of bacterial overgrowth in IBS using the lactulose H2 breath test: Comparison with 14 C-D-xylose and healthy controls. The American Journal of Gastroenterology 2005, 100:1566-1570.
41. Posserud I., Stotzer P.O., Bjornsson E.S., et al. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut 2007, 56:802-808.
42. Sharara A.I., Aoun E., bdul-Baki H., et al. A randomized double-blind placebo-controlled trial of Rifaximin in patients with abdominal bloating and flatulence. The American Journal of Gastroenterology 2006, 101:326-333.
43. Pimentel M., Park S., Mirocha J., et al. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: A randomized trial. Annals of Internal Medicine 2006, 145:557-563.
44. Atlas R.M. Probiotics: snake oil for the new millennium?. Environmental Microbiology 1999, 1:377-382.
45. Food and Agriculture Organization of the United Nations and World Health Organization Expert Consultation Report (2001). Evaluation of health and nutritional properties of probiotics in food, including powder milk with the live lactic acid bacteria.. http://www.who.int/foodsafety/publications/fs_management/en/probiotics.p df.
46. Drakes M., Blanchard T., Czinn S. Bacterial probiotic modulation of dendritic cells. Infection and Immunity 2004, 72:3299-3309.
47. Fujii T., Ohtsuka Y., Lee T., et al. Bifidobacterium breve enhances transforming growth factor beta1 signaling by regulating Smad7 expression in preterm infants. Journal of Pediatric Gastroenterology and Nutrition 2006, 43:83-88.
48. Helwig U., Lammers K.M., Rizzello F., et al. Lactobacilli, bifidobacteria and E. coli nissle induce pro- and anti-inflammatory cytokines in peripheral blood mononuclear cells. World Journal of Gastroenterology 2006, 12:5978-5986.
49. Hudspith B.N., Rouzard G., Gibson G.R., et al. Probiotic bacteria inhibit epithelial cell IL-8 production: Role of TLR receptor engagement. Gut 2006, 55:A38.
50. O'Hara A.M., O'Regan P., Fanning A., et al. Functional modulation of human intestinal epithelial cell responses by Bifidobacterium infantis and Lactobacillus salivarius. Immunology 2006, 118:202-215.
51. Schlee M., Wehkamp J., Altenhoefer A., et al. Induction of human {beta}-defensin 2 by the probiotic Escherichia coli Nissle 1917 is mediated through flagellin. Infection and Immunity 2007, 75:2399-2407.
52. Calcinaro F., Dionisi S., Marinaro M., et al. Oral probiotic administration induces interleukin-10 production and prevents spontaneous autoimmune diabetes in the non-obese diabetic mouse. Diabetologia 2005, 48:1565-1575.
53. Lammers K.M., Brigidi P., Vitali B., et al. Immunomodulatory effects of probiotic bacteria DNA: IL-1 and IL-10 response in human peripheral blood mononuclear cells. FEMS Immunology and Medical Microbiology 2003, 38:165-172.
54. Chen C.C., Louie S., Shi H.N., Walker W.A. Preinoculation with the probiotic Lactobacillus acidophilus early in life effectively inhibits murine Citrobacter rodentium colitis. Pediatric Research 2005, 58:1185-1191.
55. Hamilton-Miller J.M., Shah S., Winkler J.T. Public health issues arising from microbiological and labelling quality of foods and supplements containing probiotic microorganisms. Public Health Nutrition 1999, 2:223-229.
56. Pedersen G., Andresen L., Matthiessen M.W., et al. Expression of Toll-like receptor 9 and response to bacterial CpG oligodeoxynucleotides in human intestinal epithelium. Clinical and Experimental Immunology 2005, 141:298-306.
57. Rachmilewitz D., Katakura K., Karmeli F., et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 2004, 126:520-528.
58. Rousseaux C., Thuru X., Gelot A., et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nature Medicine 2007, 13:35-37.
59. Verdu E.F., Bercik P., Verma-Gandhu M., et al. Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice. Gut 2006, 55:182-190.
60. Verd E.F., Bercik P., Bergonzelli G.E., et al. Lactobacillus paracasei normalizes muscle hypercontractility in a murine model of postinfective gut dysfunction. Gastroenterology 2004, 127:826-837.
61. Caballero-Franco C., Keller K., De S.C., Chadee K. The VSL#3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cells. American Journal of Physiology. Gastrointestinal and Liver Physiology 2007, 292:G315-G322.
62. Zyrek A.A., Cichon C., Helms S., et al. Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair. Cellular Microbiology 2007, 9:804-816.
63. Zeng J., Li Y.Q., Zuo X.L., et al. Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhea-predominant irritable bowel syndrome. Alimentary Pharmacology & Therapeutics 2008, 28:994-1002.
64. Dunlop S.P., Hebden J., Campbell E., et al. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. The American Journal of Gastroenterology 2006, 101:1288-1294.
65. Marshall J.K., Thabane M., Garg A.X., et al. Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario. Alimentary Pharmacology & Therapeutics 2004, 20:1317-1322.
66. Madsen K., Cornish A., Soper P., et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001, 121:580-591.
67. Ma D., Forsythe P., Bienenstock J. Live Lactobacillus reuteri is essential for the inhibitory effect on tumor necrosis factor alpha-induced interleukin-8 expression. Infection and Immunity 2004, 72:5308-5314.
68. Tuomola E.M., Salminen S.J. Adhesion of some probiotic and dairy Lactobacillus strains to Caco-2 cell cultures. International Journal of Food Microbiology 1998, 41:45-51.
69. Corr S.C., Gahan C.G.M., Hill C. Impact of selected Lactobacillus and Bifidobacterium species on Listeria monocytogenes infection and the mucosal immune response. FEMS Immunology and Medical Microbiology 2007, 50:380-388.
70. Wullt M., Johansson Hagslatt M.L., Odenholt I., Berggren A. Lactobacillus plantarum 299v enhances the concentrations of fecal short-chain fatty acids in patients with recurrent clostridium difficile-associated diarrhea. Digestive Diseases and Sciences 2007, 52:2082-2086.
71. Pimentel M., Chow E.J., Lin H.C. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. The American Journal of Gastroenterology 2000, 95:3503-3506.
72. Moayyedi, P., Ford, A. C., Talley, N. J., & et al. (2008). The efficacy of probiotics in the therapy of irritable bowel syndrome: a systematic review. Gut (e-pub ahead of print).
73. Brenner D.M., Moeller M.J., Chey W.D., Schoenfeld P.S. The utility of probiotics in the treatment of irritable bowel syndrome: A systematic review. The American Journal of Gastroenterology 2009, 104:1033-1049.
74. McFarland L.V., Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World Journal of Gastroenterology 2008, 14:2650-2661.
75. Hoveyda N., Heneghan C., Mahtani K.R., et al. A systematic review and meta-analysis: Probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterology 2009, 9:15.
76. Gibson G.R., Probert H.M., Van de Loo J., et al. Dietary modulation of the human colonic microbiota: Updating the concept of prebiotics. Nutrition Research Reviews 2004, 17:259-275.
77. Guyonnet D., Chassany O., Ducrotte P., et al. Effect of a fermented milk containing Bifidobacterium animalis DN-173010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicenter, randomized, double-blind, controlled trial. Alimentary Pharmacology & Therapeutics 2007, 26:475-486.
78. Niv E., Naftali T., Hallak R., Vaisman N. The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome-a double blind, placebo-controlled, randomized study. Clinical Nutrition 2005, 24:925-931.
79. Hun L. Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS. Postgraduate Medicine 2009, 121:119-124.
80. Enck P., Zimmermann K., Menke G., et al. A mixture of Escherichia coli (DSM 17252) and Enterococcus faecalis (DSM 16440) for treatment of the irritable bowel syndrome-a randomized controlled trial with primary care physicians. Neurogastroenterology and Motility 2008, 20:1103-1109.
81. Bittner A.C., Croffut R.M., Stranahan M.C. Prescript-assist(TM) probiotic-prebiotic treatment for irritable bowel syndrome: A methodologically oriented, 2-week, randomized, placebo-controlled, double-blind clinical study. Clinical Therapeutics 2005, 27:755-761.
82. Long Z.R., Yu C.H., Yang Y., et al. Clinical observation on acupuncture combined with microorganism pharmaceutical preparations for treatment of irritable bowel syndrome of constipation type. Zhongguo Zhen Jiu 2006, 26:403-405.
83. Bausserman M., Michail S. The use of Lactobacillus GG in irritable bowel syndrome in children: A double-blind randomized control trial. The Journal of Pediatrics 2005, 147:197-201.
84. Kim H.J., Vazquez Roque M.I., Camilleri M., et al. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterology and Motility 2005, 17:687-696.
85. Niedzielin K., Kordecki H., Birkenfeld B. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299 V in patients with irritable bowel syndrome. European Journal of Gastroenterology & Hepatology 2001, 13:1143-1147.
86. Sen S., Mullan M.M., Parker T.J., et al. Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome. Digestive Diseases and Sciences 2002, 47:2615-2620.
87. Andriulli A., Neri M., Loguercio C., et al. Clinical trial on the efficacy of a new symbiotic formulation, Flortec, in patients with irritable bowel syndrome: a multicenter, randomized study. Journal of Clinical Gastroenterology 2008, 42(Suppl. 3, Pt. 2):S218-S223.
88. Enck P., Zimmermann K., Menke G., Klosterhalfen S. Randomized controlled treatment trial of irritable bowel syndrome with a probiotic E. coli preparation (DSM17252) compared to placebo. Zeitschrift für Gastroenterologie 2009, 47:209-214.
89. Kajanda K., Myllyluoma E., Rajilic-Stojanovic M., et al. Clinical trial: Multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Alimentary Pharmacology & Therapeutics 2008, 27:48-57.
90. Whorwell P.J., Altringer L., Morel J., et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. The American Journal of Gastroenterology 2006, 101:1581-1590.
91. Nobaek S., Johansson M.L., Molin G., et al. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. The American Journal of Gastroenterology 2000, 95:1231-1238.
92. Gawronska A., Dziechciarz P., Horvath A., Szajewska H. A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children. Alimentary Pharmacology & Therapeutics 2007, 25:177-184.
93. Huertas-Ceballos, A. A., Logan, S., Bennett, C., & Macarthur, C. (2009). Dietary interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood. Cochrane Database of Systematic Reviews CD003019.
94. Miele E., Pascarella F., Giannetti E., et al. Effect of a probiotic preparation (VSL[num]3) on induction and maintenance of remission in children with ulcerative colitis. American Journal of Gastroenterology 2009, 104:437-443.
95. Gionchetti P., Rizzello F., Venturi A., et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double-blind, placebo-controlled trial. Gastroenterology 2000, 119:305-309.
96. Gionchetti P., Rizzello F., Helwig U., et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003, 124:1202-1209.
97. Hart A.L., Lammers K., Brigidi P., et al. Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut 2004, 53:1602-1609.
98. Kim H.J., Camilleri M., McKinzie S., et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhea-predominant irritable bowel syndrome. Alimentary Pharmacology & Therapeutics 2003, 17:890-895.
99. McCarthy J., O'Mahony L., O'Callaghan L., et al. Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut 2003, 52:975-980.
100. Shanahan F., Guarner F., Von Wright A., et al. A one year, randomised, double-blind, placebo controlled trial of a lactobacillus or a bifidobacterium probiotic for maintenance of steroid-induced remission of ulcerative colitis. Gastroenterology 2006, 130(Suppl. 2):A44.
101. O'Mahony L., McCarthy J., Kelly P., et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles. Gastroenterology 2005, 128:541-551.
102. Kajander K., Hatakka K., Poussa T., et al. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: A controlled 6-month intervention. Alimentary Pharmacology & Therapeutics 2005, 22:387-394.
103. Kajander K., Myllyluoma E., Rajilic-Stojanovic M., et al. Clinical trial: Multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Alimentary Pharmacology & Therapeutics 2008, 27:48-57.
104. Drouault-Holowacz S., Bieuvelet S., Burckel A., et al. A double-blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome. Gastroentérologie Clinique et Biologique 2008, 32:147-152.
105. Silk D.B., Davis A., Vulevic J., et al. Clinical trial: The effects of a trans-galacto-oligosaccharide prebiotic on fecal microbiota and symptoms in irritable bowel syndrome. Alimentary Pharmacology & Therapeutics 2009, 29:508-518.
106. Smith G.D., Steinke D.T., Kinnear M., et al. A comparison of irritable bowel syndrome patients managed in primary and secondary care: The Episode IBS study. The British Journal of General Practice 2004, 54:503-507.
107. Panijel M., Burkhard I. Pro-symbioflor for the treatment of irritable colon. Jatros Naturheilkunde 1993, 2(3):1-4.
108. Ford A.C., Talley N.J., Spiegel B.M., et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: Systematic review and meta-analysis. BMJ 2008, 337:a2313.
109. Prather C.M., Camilleri M., Zinsmeister A.R., et al. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000, 118:463-468.
110. Camilleri M., Mayer E.A., Drossman D.A., et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Alimentary Pharmacology & Therapeutics 1999, 13:1149-1159.
111. Ford A.C., Brandt L.J., Young C., et al. Efficacy of 5-HT(3) antagonists and 5-HT(4) agonists in irritable bowel syndrome: systematic review and meta-analysis. The American Journal of Gastroenterology 2009, 104(7):1831-1843.
112. Kajanda K., Hatakka K., Poussa T., et al. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: A controlled 6-month intervention. Alimentary Pharmacology & Therapeutics 2005, 22:387-394.
113. Sinn D.H., Song J.H., Kim H.J., et al. Therapeutic effect of Lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome. Digestive Diseases and Sciences 2008, 53:2714-2718.
114. Tsuchiya J., Barreto R., Okura R., et al. Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome. Chinese Journal of Digestive Diseases 2004, 5:169-174.
115. Williams E., Stimpson J., Wang D., et al. Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. Alimentary Pharmacology & Therapeutics 2008, 29(1):97-103.
116. Deshpande G., Rao S., Patole S. Probiotics for prevention of necrotising enterocolitis in preterm neonates with very low birthweight: A systematic review of randomised controlled trials. The Lancet 2007, 369:1614-1620.
117. Minna K.S., Soile T., Rautelin H., et al. The efficacy and safety of probiotic Lactobacillus rhamnosus GG on prolonged, noninfectious diarrhea in HIV patients on antiretroviral therapy: A randomized, placebo-controlled, crossover study. HIV Clinical Trials 2004, 5:183-191.
118. Mego M., Ebringer L., Drgona L., et al. Prevention of febrile neutropenia in cancer patients by probiotic strain Enterococcus faecium M-74. Pilot study phase I. Neoplasma 2005, 52:159-164.
119. Boyle R.J., Robins-Browne R.M., Tang M.L. Probiotic use in clinical practice: What are the risks?. The American Journal of Clinical Nutrition 2006, 83:1256-1264.
120. Zhou J.S., Pillidge C.J., Gopal P.K., Gill H.S. Antibiotic susceptibility profiles of new probiotic Lactobacillus and Bifidobacterium strains. International Journal of Food Microbiology 2005, 98:211-217.
121. Besselink M.G., van Santvoort H.C., Buskens E., et al. Probiotic prophylaxis in predicted severe acute pancreatitis: A randomised, double-blind, placebo-controlled trial. The Lancet 2008, 371:651-659.
122. Kajander K., Hatakka K., Poussa T., et al. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: A controlled 6-month intervention. Alimentary Pharmacology & Therapeutics 2005, 22:387-394.
123. Kajander K., Myllyluoma E., Rajilic-Stojanovic M., et al. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Alimentary Pharmacology & Therapeutics 2008, 27:48-57.